Drugmakers showed off data on weight loss and diabetes drugs. Also, Oracle announced the general availability of AI documentation assistant for doctors.
The drug developments come amid growing investor interest in the treatment of metabolic diseases and specifically, a buzzy class of medications called GLP-1sBut drugmakers presented treatments that use different approaches than traditional GLP-1s such as Novo Nordisk's popular weight loss injection Wegovy and diabetes counterpart Ozempic. The two medications mimic a hormone produced in the gut to suppress a person's appetite.
Administrative tasks like paperwork are often burdensome for health-care workers, as nearly 65% of doctors feel like they are a major cause of burnout, according to a Februaryfrom Athenahealth. Physicians spend an average of 15 hours per week outside their normal hours keeping up with the workload, the survey said.
"That's just the documentation, that's not responding to lab results, patient questions, messages," he told CNBC in an interview."It can get very cumbersome trying to get your note and documentation done on top of actually doing patient care."its Clinical Digital Assistant can help alleviate this administrative burden. Doctors can access the tool through an app on their phone, and they hit a button to record their visits with patients.
Oracle has been testing the tool with 13 health-care organizations, including Hudson Physicians. Oracle said its assistant has saved clinicians an average of four and a half minutes per patient, as well as 20% to 40% of their daily documentation time. The tool is generally available in ambulatory clinics, or clinics that are not attached to hospitals, as of Monday.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why Eli Lilly shares should be up on its latest news, plus Nvidia keeps rollingEvery weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Read more »
Alphabet names Eli Lilly veteran Ashkenazi as CFOAlphabet names Eli Lilly veteran Ashkenazi as CFO
Read more »
Alphabet taps Eli Lilly's Anat Ashkenazi as new CFOThe new Google executive will replace Ruth Porat, who will become president and chief investment officer of the company after nearly a decade as CFO.
Read more »
FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »
FDA advisors recommend Eli Lilly's Alzheimer's drug donanemab, paving way for approvalIf approved, Eli Lilly's donanemab would become the second Alzheimer's drug of its kind to enter the market after Leqembi from Biogen and Eisai.
Read more »